Entero prioritises product-expansion deals above Rs 100 crore

Entero is prioritising product-expansion acquisitions with target revenue of at least Rs 100 crore, and management said it was evaluating opportunities that could close this year after first-half revenue rose 35% year-on-year to Rs 4,028 crore. Management said it is generally more interested in product expansion than geographic expansion.

What acquisition opportunities is Entero evaluating?

Entero is evaluating opportunities that expand its product portfolio or enter geographies where it has limited presence. Management identified those two areas as the broad categories for transactions under review, but said the company is generally more excited by product expansion. It said several opportunities were being evaluated during the call.

The preference reflects Entero’s effort to broaden distribution beyond pharmaceuticals, particularly in medical technology, or MedTech. Management said pharmaceutical categories are more or less covered, while MedTech still includes product categories that Entero does not handle. It cited new product categories as one of three drivers of 17%-18% organic growth, alongside customer-base expansion and increased wallet share.

Entero’s existing network provides the operating context for adding categories. In the first half, it served more than 92,200 retail customers and over 2,900 hospital customers across about 500 districts in more than 20 states and union territories. The company distributed over 90,400 stock-keeping units from more than 3,200 healthcare-product manufacturers during the period.

How large must Entero’s acquisition targets be?

Entero is not considering acquisition targets with revenue below Rs 100 crore. Management said its current scale means there is no point in evaluating very small acquisitions, though it did not set an upper revenue threshold, identify a target, or provide a potential transaction value.

That screening threshold changes the emphasis from Entero’s past deal range. Management said it had historically completed acquisitions with revenue of Rs 20 crore as well as Rs 400 crore. It also said large acquisition opportunities remain available in both pharmaceutical distribution and MedTech, without quantifying the number of opportunities or their sizes.

The Rs 100 crore threshold is a revenue criterion for targets, not a disclosed acquisition budget. Management did not state how much cash it has earmarked for transactions, and said capital allocation would depend on the opportunities available. Other uses for operating cash flow include buying minority interests and funding more aggressive organic growth.

Can Entero close an acquisition this year?

Entero said some opportunities under evaluation can be closed this year, but management did not guarantee that a transaction would be completed. In separate responses, management said it was working on multiple opportunities and was hopeful that something would happen this year. Any completed transaction would be disclosed through a stock-exchange release when it crystallises.

The timing matters because management expects the calendarisation benefit from prior acquisitions to taper partly in the third quarter and more in the fourth quarter unless new acquisitions are announced. Calendarisation refers to the additional reported revenue from a business being included for more months than in the comparable period. Management did not provide a revised second-half revenue forecast.

No new acquisition was made in the first half, based on management’s confirmation that Rs 166 crore of acquisition consideration paid in that period related to earlier deals. The payment was deferred consideration under prior agreements, rather than a call or put option payment. Management did not disclose the remaining deferred-consideration balance during the call.

Why is MedTech central to Entero’s product expansion?

MedTech accounted for more than 15% of Entero’s first-half revenue, and management confirmed that the business generated about Rs 600 crore in the period. That contribution compares with consolidated first-half revenue of Rs 4,028 crore, indicating that MedTech is already a material part of the company’s distribution mix.

Management said MedTech offers room for organic category additions, deeper penetration in existing markets and partnerships with medical-technology manufacturers. It expects the combination of pharmaceutical distribution and MedTech to use existing customer relationships and distribution infrastructure. The stated aim is to expand the range of products and services offered to customers.

Entero did not disclose a standalone MedTech earnings before interest, tax, depreciation and amortisation, or EBITDA, margin. Management said margins depend on the value added rather than simply the product sold. Plain distribution can resemble pharmaceutical distribution, while demand-generation work can carry a different margin profile in both MedTech and pharmaceutical activities.

How will Entero balance acquisitions, cash flow and debt?

Entero intends to deploy cash toward growth opportunities before debt repayment when suitable investments are available, subject to a board mandate not to exceed net debt of two times EBITDA. Management said debt repayment would remain an option if it did not find opportunities that met its return criteria. It did not disclose net debt or available borrowing capacity on the call.

Repayments on debt raised for an acquisition completed last year were scheduled to start in the third quarter. Management said the reduction of debt over time should lower interest cost, but gave no updated quarterly interest-cost forecast. It also declined to estimate future minority-interest levels because these depend on the eventual mix of acquisitions, buyouts and organic investment.

For the financial year, management reaffirmed its guidance to convert 50% of EBITDA into operating cash flow, or OCF. First-half OCF was negative Rs 46.5 crore after delayed collections on certain Maharashtra government contracts. Management said about Rs 55 crore was received in November and that first-half OCF would have been positive if that amount had arrived on the due date.

What operating performance supports Entero’s expansion plans?

Entero said first-half performance was ahead of its internal expectations and that it was comfortable delivering better than its stated FY 2027 guidance, excluding new acquisitions. That guidance called for consolidated revenue growth of about 23%, a 5% EBITDA margin and 50% EBITDA-to-OCF conversion. Management did not issue a specific revised full-year forecast.

First-half revenue increased 35% year-on-year to Rs 4,028 crore, while gross profit was Rs 461 crore and the gross margin was 11.5%. EBITDA margin was 5.2% in the first half, above the 5% margin in the existing FY 2027 guidance. Management said it expected to do better than prior guidance on both growth and margin.

Working-capital metrics were affected by the delayed government collection. Net working-capital days were 64 days in the quarter, but management said they would have been 61 days after adjusting for the November receipt, similar to the preceding quarter. First-half net working-capital days improved to 66 from 68 in the comparable prior-year period.

Conclusion

Entero’s disclosed acquisition approach now centres on larger targets that add products, particularly in MedTech, while retaining geographic expansion as a second route. The Rs 100 crore minimum target-revenue threshold contrasts with historical acquisitions as small as Rs 20 crore, and the company’s Rs 600 crore first-half MedTech revenue highlights the scale of the category platform it seeks to extend.

The next development to watch is whether an evaluated transaction reaches a stock-exchange announcement this year, as management said some opportunities could close within that period. Investors can also track third-quarter debt repayments, progress toward 50% EBITDA-to-OCF conversion, and whether the Rs 55 crore Maharashtra government receipt helps working-capital days remain near the adjusted 61-day level management cited.